key: cord-0934373-chse1mxw
authors: Zhou, Zehua; Zhang, Xinyu; Li, Qianqian; Fu, Lili; Wang, Meiyu; Liu, Shuo; Wu, Jiajing; Nie, Jianhui; Zhang, Li; Zhao, Chenyan; Jiang, Fei; An, Yimeng; Yu, Bin; Zheng, Haifa; Wang, Youchun; Zhao, Aihua; Huang, Weijin
title: Unmethylated CpG Motif-Containing Genomic DNA Fragments of Bacillus Calmette-Guerin Improves Immune Response towards a DNA Vaccine for COVID-19
date: 2021-09-03
journal: Vaccine
DOI: 10.1016/j.vaccine.2021.08.103
sha: 773aadc146204a815b75e10293819d6bab42562e
doc_id: 934373
cord_uid: chse1mxw

The development of an effective vaccine to control the global coronavirus disease-2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus- 2 (SARS-CoV-2) is of utmost importance. In this study, a synthetic DNA-based vaccine candidate, known as pSV10-SARS-CoV-2, expressing the SARS-CoV-2 spike protein was designed and tested in 39 BALB/c mice with BC01, an adjuvant derived from unmethylated CpG motif-containing DNA fragments from the Bacillus Calmette-Guerin genome. Mice vaccinated with pSV10-SARS-CoV-2 with BC01 produced early neutralizing antibodies and developed stronger humoral and cellular immune responses compared to mice that received the DNA vaccine only. Moreover, sera from mice vaccinated with pSV10-SARS-CoV-2 with BC01 can neutralize certain variants, including 614G, 614G+472V, 452R, 483A, 501Y.V2, and B.1.1.7. The results of this study demonstrate that the addition of BC01 to a DNA-vaccine for COVID-19 could elicit more effective neutralizing antibody titers for disease prevention.

Coronavirus disease 2019 (COVID-19) has emerged as a global health crisis. As of November 17, 2020, more than 55 million people were infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has caused over one million deaths [1] . SARS-CoV-2 is a single, positive-strand ribonucleic acid (RNA) virus with a spike protein that determines infectivity of the virus and transmissibility in the host [2] . The spike (S) protein of the virus is also quite unstable, with mutations potentially resulting in increased infectivity of the virus [3] [4] [5] [6] [7] . With no effective treatment currently available to the public, there is an urgent need for effective prevention methods, particularly a vaccine. Currently, 48 candidate vaccines are in clinical evaluation, and at least four of these are deoxyribonucleic acid (DNA)-based vaccines (https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vac cines).

DNA vaccines have previously been successful in preventing various infectious diseases and are advantageous compared to conventional vaccines, as their design is straightforward and only requires one-step cloning into a plasmid vector [8] . Moreover, the expression of an antigen gene in vivo can maintain native protein structures, ensuring appropriate processing and immune presentation. Unfortunately, eliciting adequate immunogenicity is still the biggest challenge for practical DNA vaccine use.

Many strategies have been applied in preclinical models to solve this problem, including formulation of DNA vaccines with molecular adjuvants [9] . Adjuvants are immunomodulators, which have been used in conjunction with vaccines to treat various clinical diseases for decades. The purpose of adding adjuvants to vaccines is to enhance, accelerate and prolong antigen-specific immune responses. For example, CpG-oligodeoxynucleotides (CpG-ODN) have been recognized as an immune adjuvant for various vaccines, because it can promote the activation of innate and adaptive immune responses in animals and humans [9] . CpG-ODN can also directly stimulate monocytes, macrophages, and dendritic cells to secrete various cytokines, such as TNF-α and GM-CSF, which in turn stimulate helper T cells to elicit immune responses [10, 11] . BC01 was derived from the unmethylated CpG motif-containing DNA fragment from the BCG genome, as it displays strong adjuvant properties [11] .

In the present study, we constructed a DNA vaccine expressing the SARS-Cov-2 S protein using BC01 as an adjuvant. The DNA vaccine with BC01 elicits effective neutralizing antibodies and cell-mediated responses to protect against SARS-CoV-2 virus infection.

DNA vaccines were designed based on the SARS-CoV-2 S protein sequence Wuhan-1 (GenBank: MN_908947). The full-length sequence of the S protein was synthesized.

Synthetic genes were cloned into the mammalian expression plasmid pSV10, and the DNA vaccine sequence was confirmed using Sanger sequencing.

The 6-well plates seeded with 293T cells at 70% confluency were transfected with pSV10-SARS-CoV-2 plasmids (4 µg) using Lipofectamine 3000 (Invitrogen). Cell lysates were harvested 48 hours post transfection, heated for five minutes at 95 °C, and run on a precast 10% SDS-PAGE gel (Bio-Rad). Proteins were transferred to a polyvinylidene difluoride (PVDF) membrane and membrane blocking was performed overnight at 4 °C in a phosphate-buffered saline T (PBST) containing 0.2% Tween 20 (Sigma) (V/V) and 5% (W/V) non-fat milk powder. Following overnight blocking, the PVDF membrane was incubated for 1 hour in 5% milk PBST containing a 1:1000 dilution of monoclonal mouse anti-SARS-CoV-2 S1 antibody. Then, the PVDF membrane was washed five times with 5% milk PBST and subsequently incubated with 1:10,000 goat anti-mouse secondary antibodies in 5% milk PBST. Thereafter, the PVDF membrane was washed again five times with 5% milk PBST, and protein expression was detected using a Touch Imager XLI system (e-BLOT).

Thirty-nine female mice, four to six weeks old, were classified into four groups: 1) pSV10-SARS-CoV-2 with BC01 (N=10), 2) pSV10-SARS-CoV-2 only (N=10), 3) BC01 only (N=10), 4) PBS only (N=9). Each mouse was intramuscularly injected with 50 μg DNA vaccine and/or 10 μg BC01, followed by CELLECTRA® in vivo electroporation (EP) at week 0, week 2, and week 4. The CELLECTRA® EP delivery consisted of two sets of pulses with 0.2 Amp constant current. Second pulse sets were delayed by 3s. Within each set there were two 52 ms pulses with a 198 ms delay between the pulses. The serum was collected at four and six weeks after immunization.

The production of SARS-CoV-2 pseudovirus was performed as described previously [12] . Briefly, the plasmid expressing the SARS-CoV-2 S protein was inserted into 293T cells, and the cells were subsequently infected with G*ΔG-VSV (VSV G pseudotyped virus) at a concentration of 7.0 × 10 4 TCID 50/ml. G*ΔG-VSV packages expression cassettes for firefly luciferase instead of VSV-G in the VSV genome.

Luciferin and luciferase, which are bioluminescent systems, can detect gene expression very sensitively and efficiently. Thereafter, the supernatant was discarded after cells were incubated for six to eight hours at 37 °C, and 15 ml fresh cell medium was added to the flask, followed by further culture for 24 hours. Finally, culture supernatants containing SARS-CoV-2 pseudotyped viruses were harvested, filtered (0.45 mm pore size, Millipore, Cat#SLHP033RB), and stored at -80 °C. SARS-CoV-2 pseudotyped viruses were measured in titers and yielded more than ten times the relative luminescence units (RLU) compared to negative controls (cells only) after 24 hours of infection.

ELISAs were performed to detect sera antibody binding titers. ELISA plates were coated with 1 µg/ml SARS-CoV-2 S protein in 1 × DPBS overnight at 4 °C. Plates were washed thrice with wash buffer and then blocked with 3% BSA in DPBS with 0.05% Tween for two to three hours at room temperature. The blocking solution was discarded, plates were washed and incubated with serial dilutions of heat-inactivated mice serum for one hour at room temperature. Plates were washed and incubated with a 1:4000 dilution of anti-mouse IgG HRP-conjugated antibody in the dark for one hour at room temperature. Plates were then washed five times with wash buffer, and 100 µL TMB solution was added to each well. The reaction was halted by the addition of 100 µL TMB Stop solution per well. The absorbance was recorded at 450 nm and 630 nm.

In addition, the neutralization level of the vaccine against the currently prevalent pseudoviruses D614G, D614G + I472V, L452R, 501Y.V2, B.1.1.7, and V483A were evaluated. The sera of five vaccinated mice from each group at week 6 were used for the neutralization test. Mouse sera from different vaccinated groups were heat inactivated for 30 minutes at 56 °C and serially diluted threefold, starting at a 1:30 dilution for each assay. Sera were mixed with 50 µL of pseudovirus for 60 minutes.

Huh-7 cells stably expressing angiotensin-converting enzyme 2 (ACE2) were added after 60 minutes, followed by incubation at 37 °C for 24 hours. Next, cells were lysed using Britelite plus luminescence reporter gene assay system (Perkin Elmer Catalog no. 6066769) and RLU values were measured. The Reed-Muench method was used to calculate the virus neutralization titer (ID 50 ).

Mice spleens were collected and ground into single cell suspensions in RPMI1640 media supplemented with one percent penicillin/streptomycin (R0). Cell pellets were resuspended in 5 mL ACK lysis buffer for 5 minutes, thereafter 8 mL PBS was added to 

We used IFN-γ ELISPOT to detect the cellular immune response. We performed epitope mapping on splenocytes of BALB/c mice receiving 50 μg of the pSV-10-SARS-CoV-2 vaccine. The S protein was covered with 20 peptide libraries.

Each peptide library contained seven peptides: each peptide had 18 amino acids, and the adjacent peptide overlapped nine amino acids. Cellular immune response was detected in multiple peptide pools, but the strongest response was in peptide pool 5, 

Analysis was performed using GraphPad Prism 8.4.2 (GraphPad Software).

Comparison of data between groups was performed using One-way ANOVA and Holm-Sidak's multiple comparisons test. P-values < 0.05 were considered statistically significant.

We produced a prototype DNA vaccine expressing the SARS-CoV-2 S protein (Fig.   1A ). pSV10-SARS-CoV-2 recombinant plasmid constructed by inserted the SARS-CoV-2 Spike protein (GenBank: MN_908947) into pSV10. The molecular weight of the S protein was 140-142 kDa, and its slight shift was due to 22 potential N-linked glycans in the S protein (Fig. 1B) . The spike protein could be expressed after transfection of the vaccine vector.

The 39 mice (aged 4-6 weeks) were immunized with the DNA vaccine: (Fig. 2A) . The pSV-10-SARS-CoV-2 with BC01 vaccine induced the development of protective neutralizing antibodies in 80% of mice, which was significantly higher than that of the pSV-10-SARS-CoV-2 group (50%). These results indicate that BC01 promotes the early production of neutralizing antibodies in mice (Table 1) .

At week 4, the binding antibody titer of the pSV-10-SARS-CoV-2 group was not significantly different from that of pSV-10-SARS-CoV-2 with BC01 group (p>0.05).

No binding antibody was detected in the BC01 and PBS only groups. At week 6, the binding antibody titer of the DNA vaccine group was not significantly different from that of pSV-10-SARS-CoV-2 with BC01 group (p>0.05). No binding antibody was detected in the BC01 and PBS only groups (Fig. 2B) . were detected in pSV-10-SARS-CoV-2 immunized mice, respectively. The BC01 and PBS only groups could not neutralize these variants (Fig. 3A-F) .

We used IFN-γ ELISPOT to detect the cellular immune response. We performed epitope mapping on spleen cells of BALB/c mice receiving 50 μg pSV-10-SARS-CoV-2 dose. The S protein was covered with 20 peptide libraries. Each peptide library contained 7 peptides, each peptide had 18 amino acids, and the adjacent peptide overlapped 9 amino acids. Cellular immune response was detected in multiple peptide pools, but the strongest response was in peptide pool 5, located at the 234-297 region (Fig. 4) . In this study, the DNA vaccine with BC01 increased the number of neutralizing antibodies earlier compared to the DNA vaccine without adjuvant. Unmethylated

CpG-ODN induces an innate immune response by triggering cells expressing Toll-like receptor 9, which is characterized by the production of Th1 and pro-inflammatory cytokines [15] . In mice, TLR-9 is expressed in multiple cells of the myeloid lineage, including monocytes, macrophages, and dendritic cells [16] [17] [18] . B cells and plasmacytoid dendritic cells are the main cell types that express TLR-9 in humans [19] [20] [21] [22] . Therefore, the BC01 binds to these immune cells expressing TLR-9 and triggers a protective immune response, enhancing the specific cellular and humoral immunity caused by the DNA vaccine. The BC01 used in this study also enhanced the neutralizing antibody titer but did not increase the binding antibody. Therefore, we hypothesized that the neutralizing antibodies and binding antibodies are evaluation indicators for the functional activity and quality of vaccine-induced humoral immune responses. Neutralizing antibodies can directly neutralize the virus, causing the virus to lose its infectious activity, and then be phagocytosed and cleared by macrophages.

After the binding antibody binds to the virus, it mediates the virus to macrophages, which in turn kills the virus, and may also cause immune damage. Neutralizing antibody and binding antibody are induced by different antigens. The results of this study revealed that the BC01 adjuvant promoted the increase of neutralizing antibody titer, but did not increase the binding antibody titer. The reason towards the expressed neutralizing antibody is higher than the immune response towards the induced binding antibody, and the adjuvant effect of BC01 is mainly reflected in the improvement of the neutralizing antibody titer. At the same time, it may also be the immune stimulating effect of BC01 itself, such as promoting the release of antigen-specific Th1 cytokines (IFN-γ, IL-2), and biasing the adaptive immune response to promote the production of neutralizing antibodies. Moreover, it has been reported that neutralizing antibodies account for less than 1% of total antibodies, so an increase in neutralizing antibodies may have no effect on the number of total antibodies [23, 24] . Otherwise, it may be the combination of the two or other unknown reasons, but the current in vivo test results exhibit that BC01 promotes the vaccine to produce a protective immune response.

Several studies suggest that the affinity of antibody to antigen determines the protective effect of antibody, and neutralization reaction is related to affinity. In this study, BC01

can improve protective immune responses induced by DNA vaccine, so further investigations on whether BC01 play a role in vaccines that cause higher affinity antibodies are imperative.

In order to evaluate the vaccine in this study, only detecting the binding antibody may not accurately reflect the immunogenicity induced by the vaccine. The pseudovirus-based neutralization antibody assay used in this study has been validated by previous studies [25] [26] [27] [28] , which correlates well with the live virus-based neutralization assay, and can be used for neutralization antibody evaluation.

SARS-CoV-2 is a single-stranded positive RNA virus, which has a higher mutation rate than DNA viruses [29] [30] [31] . At present, studies have found many mutations in the S protein gene of SARS-CoV-2, of which D614G is the most important mutation along with combined mutations, such as D614G + I472V [32] [33] [34] . Other studies have found that certain mutation sites can reduce the infectivity of the virus, such as L452R and V483A, but these sites can tolerate some neutralizing antibodies [34] . Furthermore, the B.1.1.7 variant includes many genetic changes, and has been increasing rapidly in the United Kingdom. This variant may be increasing human ACE2 binding due to an N501Y mutation [35] . The emergence of unique South African lineages (501Y.V2) also include multiple non-synonymous S protein mutations that may have functional significance, such as K417N, E484K, and N501Y in the S-receptor-binding domain [36] . The pSV10-SARS-CoV2 vaccine used in this study was found to neutralize some mutations, but not the L452R and 501Y.V2 variants. However, the pSV10-SARS-CoV2 with BC01 vaccine can neutralize these mutant strains, as it induces higher neutralizing antibody titers. Thus, DNA vaccines with BC01 can provide a more effective neutralizing activity to defend against SARS-CoV-2 infection.

However, further research is warranted to determine whether the DNA vaccine can neutralize all mutant strains.

A DNA pSV10-SARS-CoV2 vaccine with the addition of a BC01 adjuvant improves efficacy and increases the cellular and humoral immune response in mice. Further research is needed to determine how this adjuvant may impact human trials and if it can be incorporated into ongoing vaccine trials for the prevention of COVID -19.

The authors declare no potential conflicts of interest. ELISPOT assay at week 6.

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Table1 Neutralizing activity of sera after pSV10-SARS-CoV-2 with BC01 administration to mice 

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Coronavirus Spike Protein and Tropism Changes

Mutated COVID-19 may foretell a great risk for mankind in the future

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

A virus that has gone viral: amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding, and thus, infectivity

Emergence of genomic diversity and recurrent mutations in SARS-CoV-2

SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate

DNA vaccines: developing new strategies to enhance immune responses

Molecular mechanisms for enhanced DNA vaccine immunogenicity

Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation

Unmethylated CpG motif-containing genomic DNA fragment of Bacillus calmette-guerin promotes macrophage functions through TLR9-mediated activation of NF-kappaB and MAPKs signaling pathways

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect

Immunogenicity of a DNA vaccine candidate for COVID-19

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

CpG DNA as a vaccine adjuvant

Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens

Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12

Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells

A Toll-like receptor recognizes bacterial DNA

Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells

Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide

Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides

Avidity assay to test functionality of anti-SARS-Cov-2 antibodies. Vaccine

The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2

A Thermostable mRNA Vaccine against COVID-19

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus

Why are RNA virus mutation rates so damn high?

Quasispecies theory and the behavior of RNA viruses

SARS-CoV-2 spike D614G variant confers enhanced replication and transmissibility. bioRxiv

Spike mutation D614G alters SARS-CoV-2 fitness

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

We thank the support from Dr. Yang Yu of National institutes for Food and Drug Control for providing regents.